Regeneron announced a series of leadership changes Friday, including a transition at the CFO level and updates to the composition of the board of directors.
The company announced that CFO Robert E. Landry is retiring from his role in February 2024 and will be replaced by Christopher Fenimore, a two-decade veteran of the company who currently serves as SVP, head of accounting and controller.
He previously served as VP of financial planning at Regeneron after joining following a stint in leadership at Mojave Therapeutics, a biopharma startup. Fenimore will report directly to Regeneron CEO Leonard S. Schleifer, MD, PhD in the new role.
“Bob has been an invaluable contributor during a tremendous period of growth and evolution for Regeneron,” Schleifer said in a statement. “We thank him for his dedicated service as CFO, his steady hand and his incredible work ethic over the past decade. We also look forward to welcoming Chris to his new role in early 2024, knowing he brings similar rigor and depth of financial knowledge that will ensure continuity and collaboration across the organization.”
Additionally, the company announced that Kathryn Guarini, PhD and David P. Schenkein, MD joined Regeneron’s board of directors effective September 8.
Guarini recently retired as the chief information officer at IBM, a position she held for more than two decades.
Schenkein, meanwhile, is a general partner and co-lead of the life sciences team at Google Ventures (GV). Before joining GV in 2019, she served as CEO of Agios Pharmaceuticals for a decade. He previously served in C-suite positions at Genentech and Millennium Pharmaceuticals.
While the company added Guarini and Schenkein to its board, Regeneron announced the departure of Marc Tessier-Lavigne, PhD effective September 1. He had served on the board since 2011 and retired from the position due to “potential conflicts that may arise as he becomes more involved with other companies.”
Tessier-Lavigne made headlines earlier this summer when he announced his resignation as president of Stanford University following a probe of his past research as a neuroscientist. He left his post on August 31.
“Today’s announcement demonstrates our strong commitment to strategic refreshment of the Board, a focus on the recruitment of new directors to complement the overall mix of skills, experience and perspectives, and further enhancement of the Board’s diversity,” said Christine Poon, the lead independent director of Regeneron’s board, in a statement.